Jul 22, 2026 · 1h 12m
Longevity startup bypasses Silicon Valley to build in Japan
Why this longevity startup raised in Japan, not Silicon Valley | TWiST Tokyo | E2315
The episode highlights how international regulatory environments and alternative funding structures are challenging Silicon Valley's monopoly on deep-tech innovation.
- 1Japan offers a highly supportive regulatory framework and specialized research hubs like Okinawa for life extension technologies.
- 2Startups in Japan can leverage government-backed loans and cheaper epigenetic data to maintain high capital efficiency.
- 3Flipping to a United States entity remains a viable strategy for Japanese startups seeking global venture capital.
Don't miss
Bilal Kharouni details how epigenetic data and methylation tracking are used to benchmark biological age against chronological age.
The brief
At a live Founder University session in Tokyo, entrepreneur Bilal Kharouni of Ekei Labs explains why Japan is emerging as a premier launchpad for longevity startups, defying the traditional Silicon Valley playbook.
Japan offers a highly supportive regulatory framework, strategic research hubs like Okinawa, and access to unique government-backed startup loans that allow founders to maintain higher equity and capital efficiency.
By utilizing low-cost epigenetic data and methylation tracking, Ekei Labs aims to accelerate drug discovery and cell therapy, leveraging Japan's favorable rules around clinical testing and patient access.
Building outside the US requires strategic flexibility, such as flipping to a US entity later for venture capital, while prioritizing personal health and sleep to survive the intense startup grind.
Featuring
Japan
Epigenetics
Cell therapy
Drug discovery
Founder UniversityBooks & mentions
This Week in Startups
Explore more interviews with global tech founders and discussions on venture capital dynamics
Listen to the full episode and explore every guest, topic, and moment on PodLume.